KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other financing activities (2020 - 2022)

Historic Other financing activities for Halozyme Therapeutics (HALO) over the last 5 years, with Q4 2022 value amounting to $639000.0.

  • Halozyme Therapeutics' Other financing activities changed N/A to $639000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was $1.1 million, marking a year-over-year decrease of 8450.17%. This contributed to the annual value of $4.9 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Halozyme Therapeutics reported Other financing activities of $639000.0 as of Q4 2022.
  • Over the past 5 years, Halozyme Therapeutics' Other financing activities peaked at $6.0 million during Q2 2022, and registered a low of -$68000.0 during Q2 2020.
  • Its 3-year average for Other financing activities is $1.1 million, with a median of $329000.0 in 2021.
  • Per our database at Business Quant, Halozyme Therapeutics' Other financing activities soared by 23970.59% in 2021 and then surged by 621894.74% in 2022.
  • Quarter analysis of 3 years shows Halozyme Therapeutics' Other financing activities stood at -$68000.0 in 2020, then surged by 239.71% to $95000.0 in 2021, then surged by 572.63% to $639000.0 in 2022.
  • Its last three reported values are $639000.0 in Q4 2022, $462000.0 for Q3 2022, and $6.0 million during Q2 2022.